CAN002 is a supersaturated calcium phosphate oral rinse solution indicated for mucositis caused by radiation or high dose chemotherapy. CAN002 has been approved and marketed in 47 countries as a medical device for cancer adjuvant therapy. Plenty of clinical data has indicated that CAN002 is highly effective in preventing and treating mucositis with excellent safety profile.
CANbridge has the exclusive distribution right of CAN002 in China.
Mucositis is the painful inflammation and ulceration of the mucous membranes lining the digestive tract, usually as an adverse effect of chemotherapy and radiotherapy treatment for cancer. Mucositis can occur anywhere along the gastrointestinal (GI) tract, but oral mucositis refers to the particular inflammation and ulceration that occurs in the mouth. Oral mucositis is a common and often debilitating complication of cancer treatment.
Oral mucositis affects almost all patients undergoing high-dose chemotherapy and hematopoietic stem cell transplantation (HSCT), 80% of patients with malignancies of the head and neck receiving radiotherapy, and a wide range of patients receiving chemotherapy. or most cancer treatment, about 5–15% of patients get mucositis. However, with 5-fluorouracil (5-FU), up to 40% get mucositis, and 10–15% get grade 3–4 oral mucositis.